Title |
Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis
|
---|---|
Published in |
Frontiers in oncology, October 2016
|
DOI | 10.3389/fonc.2016.00231 |
Pubmed ID | |
Authors |
Ajit Venniyoor, Bassim Al Bahrani |
Abstract |
Skin rash is a side effect of drugs that inhibit epithelial growth factor receptor (EGFR) as a part of targeted therapy of cancer. Its appearance and severity correlates with survival. Minocycline, an oral tetracycline antibiotic, is recommended as treatment (and increasingly, for prevention) of the rash, though infection is seen in only one-third of the patients. Minocycline has additional anticancer properties such as poly(ADP-ribose) polymerase inhibition. It is proposed that such properties contribute to the efficacy of EGFR inhibitors and can also explain the positive correlation between grade of rash and survival as patients with higher grades of rash are more likely to receive minocycline. Early concurrent administration of minocycline is recommended in patients planned for EGFR therapy while awaiting trials proving this hypothesis. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 9 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 2 | 22% |
Student > Bachelor | 2 | 22% |
Other | 1 | 11% |
Professor | 1 | 11% |
Researcher | 1 | 11% |
Other | 0 | 0% |
Unknown | 2 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 44% |
Psychology | 2 | 22% |
Unknown | 3 | 33% |